income 219 146 50.2% 127 72.5% Gross profit 2,367 2,214 6.9% 2,320 2.0% SG&A 1,538 1,322 16.3% 1,446 6.3% Selling and distribution expenses 1,050 884 18.8% 1,002 4.7% Administrative expenses 488 438 11.2
business in the Philippines THB 24 million, and share of profit from the geothermal power plant business in Indonesia THB 67 million. Bio-Based Product Business, by the Biodiesel Production and Distribution
. Meanwhile, domestic branded sales slightly increased. Net loss in Q2/2018 was Baht 15 million, a decrease due to 1) a one-time cost of financial advisory fees and legal consultant fees of Baht 22 million
for sales staff, traveling and vehicle expense for sales staff, cost of advertisement media for product promotion, compensation paid to Zuellig Pharma Ltd. under the Distribution Agreement and
expense for sales staff, cost of advertisement media for product promotion, compensation paid to Zuellig Pharma Ltd. under the Distribution Agreement and compensation for distribution of the Company’s
) (5,394.3) (657.9) 12.2 Gross profit 2,828.3 2,679.0 149.3 5.6 Gross profit margin 31.8% 33.2% Distribution and Administrative expenses (1,231.7) (1,131.9) (99.8) 8.8 Operating Profit 1,596.6 1,547.1 49.5 3.2
Million, representing an increase from the previous year by Baht 2,160 Million or 16. 3 percent. The revenue increased from all 3 businesses but mainly from the Si Rat-Outer Ring Road Expressway ( SOE) and
year 2018, revenues from sales and services from Distributor of medical devices and equipment is THB 1,828 million increased by 3% compared with the same period last year. Over the next three years
, equal to 20 percent of its issued and paid-up share capital from its existing shareholders. As a result of this transaction, the Company’s shareholding in BMN increased from 69.67 percent to 89.67 percent